Drug Trial Radar · NCT06015282
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,741
Actual
Start
Nov 3, 2023
Primary completion
Mar 5, 2024
Study completion Jan 30, 2025
Sponsor
- Lead sponsor
- SeqirusIndustry
- Sponsor type
- Industry
- First posted
- Aug 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally split between two age groups: 50-64 years; 65 years and older), who are healthy or have stable comorbidities that increase their risk of complications from influenza infection. Three lots of aQIVc will be evaluated for consistency and pooled for the comparison with the 2 control vaccines. Subjects will be randomly assigned to receive 1 of 3 lots of aQIVc, QIVr, or aQIV in a 1:1:1:2:2 ratio (for a 3:2:2 ratio for aQIVc, QIVr, and aQIV). The study will have a treatment period (Day 1 to Day 29) and a follow-up period (Day 30 up to Day 181); a subset of 770 subjects will be followed up up to Day 365.
Conditions
- Influenza, Human
Interventions
Investigational aQIVcBiological
Investigational Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
licensed QIVrBiological
Recombinant Quadrivalent Influenza Vaccine (Flublok Quadrivalent/Supemtek) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
licensed aQIVBiological
Adjuvanted, egg-derived Quadrivalent Influenza Vaccine (Fluad) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immunogenicity Endpoint: Humoral immune responses of 3 lots of aQIVc compared in pairs in terms of Day 29 GMT ratio between each pair among the 3 lots, from antibody titers measured via HI assay.Time frame: Day 29
- Immunogenicity Endpoint: Humoral immune responses of aQIVc in comparison with QIVr and aQIV vaccines in terms of Day 29 GMT and GMT ratio of antibodies measured via HI assay.Time frame: Day 29
- Immunogenicity Endpoint: Humoral immune responses of aQIVc in comparison with QIVr and aQIV vaccines in terms of Day 1 to Day 29 SCR and SCR difference, from antibody titers measured via HI assay.Time frame: Day 1 and Day 29
Locations
96 sites in 8 countries. Site status is shown where the registry gives one.
Alliance for Multispecialty Research (AMR) Phoenix
Tempe, Arizona
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Marvel Clinical Research
Huntington Beach, California
Paradigm Clinical Research Center, LLC
Redding, California
Clinical Research Consulting, Inc.
Milford, Connecticut
Chase Medical Research, LLC
Waterbury, Connecticut
Innovative Research of West Florida, Inc.
Clearwater, Florida
USA and International Research Inc.
Doral, Florida
Velocity Clinical Research, New Smyrna Beach
Edgewater, Florida
Health Awareness, Inc.
Jupiter, Florida
ARS - Lake Oconee
Largo, Florida
Global Health Research Center
Miami Lakes, Florida
Precision Clinical Research
Sunrise, Florida
Global Health Research center
Tampa, Florida
Velocity Clinical Research- Boise
Meridian, Idaho
Great Lakes Clinical Trials, LLC Ravenswood dba Flourish Research
Chicago, Illinois
Great Lakes Clinical Trials, LLC. Ravenswood dba Flourish Research
Gurnee, Illinois
Velocity Clinical Research Valparaoso
Valparaiso, Indiana
Velocity Clinical Research, Sioux City
Sioux City, Iowa
Velocity Clinical Research, Baton Rough
Baton Rouge, Louisiana
Benchmark Research
Metairie, Louisiana
IMA Evaluations LLC
Monroe, Louisiana
Centennial Medical Group, PC
Columbia, Maryland
Velocity Clinical Research Rockville
Rockville, Maryland
Velocity Clinical Research Gulfport
Gulfport, Mississippi
Alliance for Multispecialty Research, LLC
Kansas City, Missouri
Sundance Clinical Research
St Louis, Missouri
Velocity Clinical Research, Norfolk
Norfolk, Nebraska
Velocity Clinical Research, Omaha
Omaha, Nebraska
Alliance for Multispecialty Research (AMR) LLC, Las Vegas
Las Vegas, Nevada
Velocity Clinical Research, Binghamton
Binghamton, New York
Velocity Clinical Research, Syracuse
East Syracuse, New York
Velocity Clinical Research, Vestal
New York, New York
M3 Wake Research, Inc
Raleigh, North Carolina
CTI Clinical Research Center
Cincinnati, Ohio
Velocity Clinical Research Cincinnati
Cincinnati, Ohio
Velocity Clinical Research, Cleveland
Cleveland, Ohio
Velocity Clinical Research - Medford
Medford, Oregon
Velocity Clinical Research-Providence
East Greenwich, Rhode Island
Velocity Clinical Research, Gaffney
Gaffney, South Carolina
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.